The role of eosinophils in inflammatory bowel disease

Gut

Volumn 54, Issue 12, 2005, Pages 1674-1675

  Al Haddad, S ^a,c   Riddell, R H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; EOTAXIN; INTERLEUKIN 5;

BLOOD CELL; CELL ACTIVATION; CELL FUNCTION; CELL SURVIVAL; CROHN DISEASE; ENTERITIS; EOSINOPHIL; GASTROINTESTINAL TRACT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; NEUTROPHIL; NOTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; EOSINOPHILS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 28144452006     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.072595     Document Type: Note

References (30)

1. Mishra A, Hogan SP, Lee JJ, et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999;103:1719-27.
2. Rothenberg ME. Gastrointestinal eosinophils. Allergy 2001;56(suppl 67):21-2.
3. Daugherty BL, Siciliano SJ, DeMartino JA, et al. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996;183:2349-54.
4. Rothenberg ME. Gastrointestinal eosinophils. Immunol Rev 2001;179:139-55.
5. Lampinen M, Carlson M, Hakansson LD, et al. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004;59:793-805.
6. Lampinen M, Rönnblom A, Amin K, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005;54:1714-20.
7. Forbes E. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol 2004;172:5664-75.
8. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-4.
9. Gerber BO, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes colocalizing with eosnophils. Curr Biol 1997;7:836-43.
10. Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97:1452-7.
11. Chen W, Paulus B, Shu D, et al. Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol 2001;36:515-20.
12. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-56.
13. Wallaert B, Desreumaux P, Copin MC, et al. Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. J Exp Med 1995;182:1897-904.
14. Desneumaux P, Bloget F, Seguy D, et al. Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology 1996;110:768-74.
15. Lampinen M, Carlson M, Sangfelt P, et al. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001;46:2004-9.
16. Vallance BA, Blennerhassett PA, Deng Y, et al. IL-5 contributes to worm expulsion and muscle hypercontractility in a primary T. spiralis infection. Am J Physiol 1999;277:G400-8.
17. Carvalho AT, Elia CC, de Souza HS, et al. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol 2003;36:120-5.
18. Gonzalo JA, Lloyd CM, Kremer L, et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 1996;98:2332-45.
19. Yamada T, Grisham MB. Role of neutrophil-derived oxidants in the pathogenesis of intestinal inflammation. Klin Wochenscnr 1991;69:988-94.
20. Dvorak AM, Monahan RA, Osage JE, et al. Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 1980;11:606-19.
21. King T, Biddle W, Bhatia P, et al. Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis. Dig Dis Sci 1992;37:490-5.
22. Nolte H, Spjeldnaes N, Kruse A, et al. Histamine release from gut mast cells from patients with inflammatory bowel diseases. Gut 1990;31:791-4.
23. Bischoff SC, Wedemeyer J, Herrmann A, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996;28:1-13.
24. Lorentz A, Schwengberg S, Mierke C, et al. Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease. Eur J Immunol 1999;29:1496-503.
25. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004;10:309-18.
26. Akers IA, Parsons M, Hill MR, et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Lung Cell Mol Physiol 2000;278:L193-201.
27. Berger P, Perng DW, Thabrew H, et al. Tryptase and agonists or PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 2001;91:1372-9.
28. Gelbmann CM, Mestermann S, Gross V, et al. Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999;45:210-17.
29. Xu X, Rivkind A, Pikarsky A, et al. Mast cells and eosinophils have a potential profibrogenic role in Crohn disease. Scand J Gastroenterol 2004;39:440-7.
30. Hibi T, Inoue N, Ogata H, et al. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003;38(suppl 15):36-42.